Zoetis (NYSE:ZTS) Stock Sale Reported by Sen. Shelley Moore Capito

Senator Shelley Moore Capito (Republican-West Virginia) recently sold their entire stake in Zoetis Inc. (NYSE:ZTS). In a filing disclosed on November 4th, the Senator disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on October 21st.

Senator Shelley Moore Capito also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 10/21/2026.

Zoetis Trading Up 6.8%

Shares of Zoetis stock opened at $88.60 on Thursday. The stock has a fifty day moving average price of $75.50 and a 200-day moving average price of $93.03. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The firm has a market cap of $36.61 billion, a PE ratio of 14.60, a P/E/G ratio of 1.23 and a beta of 0.67. Zoetis Inc. has a 1 year low of $68.77 and a 1 year high of $132.49.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the previous year, the firm posted $1.76 earnings per share. The company’s revenue for the quarter was down .2% on a year-over-year basis. Equities research analysts anticipate that Zoetis Inc. will post 6.15 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be given a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 annualized dividend and a yield of 2.4%. Zoetis’s payout ratio is currently 34.93%.

Analyst Ratings Changes

Several equities research analysts have issued reports on ZTS shares. BNP Paribas Exane dropped their target price on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. William Blair lowered Zoetis from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 6th. Piper Sandler dropped their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, August 10th. Weiss Ratings raised shares of Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 29th. Finally, Zacks Research upgraded shares of Zoetis from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. Six analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $93.79.

Hedge Funds Weigh In On Zoetis

A number of hedge funds have recently bought and sold shares of ZTS. University of Texas Texas AM Investment Management Co. acquired a new position in Zoetis during the second quarter worth $25,000. Dunhill Financial LLC grew its stake in Zoetis by 519.3% during the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after buying an additional 296 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new position in Zoetis in the first quarter valued at $28,000. Root Financial Partners LLC increased its holdings in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. Finally, Wellington Grp LLC raised its holdings in Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Senator Capito

Shelley Moore Capito (Republican Party) is a member of the U.S. Senate from West Virginia. She assumed office on January 3, 2015. Her current term ends on January 3, 2027. Capito (Republican Party) ran for re-election to the U.S. Senate to represent West Virginia. She won in the general election on November 3, 2020. Capito was first elected to the Senate in 2014, becoming the first female U.S. Senator in the state’s history. Prior to serving in the Senate, Capito was a member of the West Virginia House of Representatives from 1997 to 2001 and a member of the United States House of Representatives from 2001 to 2015. At the start of the 116th Congress, Capito was a member of the U.S. Senate committees on Appropriations, Commerce, Science, and Transportation, Environment and Public Works, and Rules and Administration. As of a 2014 analysis of multiple outside rankings, Capito is a more moderate right of center Republican Party vote. As a result, she may break with the Republican Party line more than her fellow members. Capito earned her bachelor’s degree from Duke University. After earning her M.Ed. from the University of Virginia, Capito was a college counselor and then director of an educational information center. She was the only Republican in the West Virginia congressional delegation until the 2010 elections and is the first Republican woman elected to Congress from West Virginia. Capito is a former chairwoman of the Congressional Caucus for Women’s Issues, as well as a member of the Congressional Arts Caucus. After an explosion responsible for the death of 29 coal workers, Capito founded the Congressional Coal Caucus. Prior to her election to the U.S. House, Capito served in the West Virginia House of Delegates.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.